• 1
    Boileau I., Payer D., Chugani B., Lobo D., Behzadi A., Rusjan P. et al. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction 2013; 108: 953963.
  • 2
    Holden C. Psychiatry. Behavioral addictions debut in proposed DSM-V. Science 2010; 327: 935.
  • 3
    Potenza M. N. Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Phil Trans R Soc Lond B Biol Sci 2008; 363: 31813189.
  • 4
    Leeman R. F., Potenza M. N. Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) 2012; 219: 469490.
  • 5
    Potenza M. N. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry 2001; 6: 217226.
  • 6
    Linnet J., Peterson E., Doudet D. J., Gjedde A., Moller A. Dopamine release in ventral striatum of pathological gamblers losing money. Acta Psychiatr Scand 2010; 122: 326333.
  • 7
    Clark L., Stokes P. R., Wu K., Michalczuk R., Benecke A., Watson B. J. et al. Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage 2012; 63: 4046.
  • 8
    Steeves T. D., Miyasaki J., Zurowski M., Lang A. E., Pellecchia G., Van Eimeren T. et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009; 132: 13761385.
  • 9
    Potenza M. N., Walderhaug E., Henry S., Gallezot J. D., Planeta-Wilson B., Ropchan J. et al. Serotonin 1B receptor imaging in pathological gamblers. World J Biol Psychiatry doi:10.3109/15622975.2011.598559.
  • 10
    Hu J., Henry S., Gallezot J. D., Ropchan J., Neumaier J. F., Potenza M. N. et al. Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry 2010; 67: 800803.
  • 11
    Narendran R., Slifstein M., Guillin O., Hwang Y., Hwang D. R., Scher E. et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006; 60: 485495.
  • 12
    Searle G., Beaver J. D., Comley R. A., Bani M., Tziortzi A., Slifstein M. et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010; 68: 392399.
  • 13
    Tziortzi A. C., Searle G. E., Tzimopoulou S., Salinas C., Beaver J. D., Jenkinson M. et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011; 54: 264277.
  • 14
    Bullock S. A., Potenza M. N. Pathological gambling: neuropsychopharmacology and treatment. Curr Psychopharmacol 2012; 1: 6785.
  • 15
    Rylands A. J., Hinz R., Jones M., Holmes S. E., Feldmann M., Brown G. et al. Pre- and postsynaptic serotonergic differences in males with extreme levels of impulsive aggression without callous unemotional traits: a positron emission tomography study using (11)C-DASB and (11)C-MDL100907. Biol Psychiatry 2012; 72: 10041011.
  • 16
    Urban N. B., Girgis R. R., Talbot P. S., Kegeles L. S., Xu X., Frankle W. G. et al. Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [(1)(1)C]DASB and [(1)(1)C]MDL 100907. Neuropsychopharmacology 2012; 37: 14651473.
  • 17
    Girgis R. R., Slifstein M., Xu X., Frankle W. G., Anagnostou E., Wasserman S. et al. The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: a PET study with [(1)(1)C]MDL 100907 and [(1)(1)C]DASB. Psychiatry Res 2011; 194: 230234.
  • 18
    Nakazawa S., Yokoyama C., Nishimura N., Horisawa T., Kawasaki A., Mizuma H. et al. Evaluation of dopamine D(2)/D (3) and serotonin 5-HT (2A) receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. Psychopharmacology (Berl) 2013; 225: 329339.
  • 19
    Nogami T., Takano H., Arakawa R., Ichimiya T., Fujiwara H., Kimura Y. et al. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [11C]DASB and (S,S)-[18F]FMeNER-D2. Int J Neuropsychopharmacol 2012; doi: 10.1017/S1461145712001009.